🔎 Trials Near Me

Akèy › Sipwa › Florid › Orlando

Etid klinik pou Sipwa nan Orlando, FL

27 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Ap rekriteFaz 2
  • Charter Research - Winter Park /ID# 281968, Orlando
  • Florida Institute For Clinical Research /ID# 282739, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07752979

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Ap rekrite
  • Orlando Health, Inc., Orlando
Laj 21 a 65 · Tout sèks · Mizajou Oct 1, 2026 · NCT07090005

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

Ap rekriteFaz 1Volontè an sante akeyi
  • Kailera Clinical Site, Orlando
Laj 18 a 85 · Tout sèks · Mizajou Oct 1, 2026 · NCT07793929

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Ap rekriteFaz 3
  • Florida Institute for Clinical Research, LLC, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07533175

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Ap rekriteFaz 2
  • Clinical Site Partners, LLC DBA Flourish Research, Winter Park · 5 mi lwen
  • K2 Medical Research Maitland LLC, Main Office, Maitland · 6 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Ap rekriteFaz 2
  • Clinical Neuroscience Solutions, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Ap rekriteFaz 3
  • Clinical Neuroscience Solution, Orlando
  • Florida Institute for Clinical Research, LLC, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Ap rekriteFaz 3
  • Florida Inst For Clin Res LLC, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Ap rekriteFaz 3
  • Headlands Research Orlando, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Ap rekriteFaz 3
  • Orlando Health, Orlando
  • Digestive and Liver Center of Florida, Orlando
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Ap rekriteFaz 3
  • Florida Hospital- Center for Pediatric Research, Orlando
  • Nemours Children's Health, Orlando
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ap rekriteFaz 3
  • Orlando Health, Orlando
  • Digestive and Liver Center of Florida, Orlando
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Ap rekriteFaz 3
  • Clinical Site Partners, LLC dba Flourish Research, Winter Park · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Ap rekriteFaz 3
  • Research Site, Ocoee · 10 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Ap rekriteFaz 3
  • West Orange Endocrinology, Ocoee · 10 mi lwen
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Ap rekriteFaz 3
  • Conquest Research, Winter Park · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Ap rekriteFaz 2
  • Charter Research - Winter Park, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Ap rekriteFaz 3
  • AURORA-1 Clinical Site, Winter Park · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Ap rekriteFaz 3
  • AURORA-2 Clinical Site, Winter Park · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

Feasibility and Acceptability of a Pediatric Referral to Summer Day Camps to Treat Obesity in Children From Low-Income Households

Ap rekrite
  • University of Central Florida, Orlando
Laj 5 a 11 · Tout sèks · Mizajou Sep 14, 2026 · NCT07464015

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Ap rekriteFaz 3Volontè an sante akeyi
  • ACCOMPLISH-2 Research Site, Ocoee · 10 mi lwen
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Ap rekriteFaz 2
  • Charter Research - Winter Park, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Ap rekriteFaz 3
  • Kailera Clinical Site, Orlando
  • Kailera Clinical Site, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Ap rekriteFaz 3
  • Clinical Neuroscience Solutions - Orlando, Orlando
  • Combined Research Orlando Phase I IV, Orlando
  • Florida Institute for Clinical Research, Orlando
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Ap rekriteFaz 3
  • Florida Institute for Clinical Research, Orlando
  • Conquest Research - Winter Park, Winter Park · 5 mi lwen
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684144

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Ap rekriteFaz 3
  • Clinical Neuroscience Solutions, Orlando
  • Florida Institute for Clinical Research, Orlando
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Ap rekriteFaz 3
  • ACCOMPLISH-1 Research Site, Ocoee · 10 mi lwen
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Etid Sipwa nan lòt vil

Lòt etid nan Orlando

Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.